NASDAQ$PAYS

Paysign Inc · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

Paysign's second-quarter financial results reflected substantial revenue growth and increased profitability.

Paysign reported a strong second quarter with a 29.8% increase in revenue and a 95.8% increase in adjusted EBITDA. Growth was driven by the plasma donor compensation business and the patient affordability business. The company is raising its full-year guidance due to this outperformance.

  • Revenues grew by 29.8% year-over-year.
  • Adjusted EBITDA increased by 95.8% year-over-year.
  • Gross margin percentage increased by 207 basis points.
  • Full-year revenue guidance was raised.

Headline financials

Total Revenue

$14.3M

Previous: $11M+29.8%
EPS

$0.01

Previous: -$0.00+602.5%
Capital Expenditures

-$196K

Previous: -$84.9K-131.0%
Free Cash Flow

$501K

Previous: -$189K+365.0%
Net Income

$697K

Previous: -$104K+769.3%
Operating Income

$126K

Previous: -$647K+119.4%
Gross Profit

$7.59M

Previous: $5.62M+35.1%
Stock-Based Comp

$670K

Previous: $830K-19.3%

Revenue & EPS history

Paysign · Revenue · Quarterly

$14.3M

Q2 2024+29.8%vs Q2 2023
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Forward guidance

Paysign raised its full year 2024 guidance, expecting total revenues between $56.5 million and $58.5 million, gross profit margins between 54.0% and 55.0%, operating expenses between $30.0 million and $32.0 million, interest income between $3.0 million and $3.2 million, a tax rate between 28.0% and 29.0%, and net income between $2.0 million and $3.0 million.

Tailwinds

  • Total revenues are estimated to be in the range of $56.5 million to $58.5 million.
  • Plasma revenues are estimated to account for approximately 78% of total revenue.
  • Pharma revenue is estimated to account for approximately 20% of total revenue.
  • Full-year gross profit margins are expected to be between 54.0% and 55.0%.
  • Interest income of $3.0 million to $3.2 million expected.

Headwinds

  • Operating expenses are expected to be between $30.0 million and $32.0 million.
  • Tax rate to be between 28.0% and 29.0%.
  • Fully diluted share count outstanding to be 55.8 million to 56.0 million.
  • Net income to be in the range of $2.0 million to $3.0 million, or $0.04 to $0.06 per diluted share.
  • Adjusted EBITDA to be in the range of $9.0 million to $10.0 million (15.0% to 17.0% of total revenues), or $0.16 to $0.18 per diluted share

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

+16.3%

Avg return

Earnings day

+5.5%

Avg return

5 days after

+9.6%

Avg return

30 days after

43%

26 / 60 earnings

Positive

+900.0%

Q3 2011

Best reaction

-29.6%

Q4 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-12.6%-12.0%
Q4 2025+37.3%+52.8%+65.0%
Q3 2025+0.2%-8.8%+0.4%
Q1 2025+3.0%+22.9%+81.9%
Q4 2024-8.5%-14.5%-8.1%
Q3 2024+10.9%+8.7%-7.9%
Q2 2024-6.7%-14.4%-9.2%
Q1 2024-0.4%+5.4%-7.6%
Q4 2023+20.5%+10.2%+31.9%
Q3 2023+18.1%+21.6%+18.1%
Q2 2023+6.4%+8.6%+16.0%
Q1 2023-1.8%-4.5%-20.7%
Q4 2022+4.2%+7.6%+0.3%
Q3 2022-10.4%+8.9%+16.5%
Q2 2022+7.4%+15.3%+33.5%
Q1 2022-26.2%-20.2%-2.4%
Q4 2021-6.6%-16.6%-21.4%
Q3 2021-9.0%-14.6%-32.8%
Q2 2021-2.4%+5.6%+16.7%
Q1 2021-11.4%-10.8%+0.0%
Q4 2020+11.7%+5.1%+0.8%
Q3 2020-26.8%-20.6%-7.7%
Q2 2020-18.9%-30.5%-45.3%
Q1 2020-5.5%-13.0%-0.4%
Q4 2019+27.3%+82.9%+102.7%
Q3 2019+13.2%+17.1%+3.9%
Q2 2019+2.5%+6.3%+2.7%
Q1 2019-11.7%-6.7%+18.2%
Q4 2018-1.7%-7.5%-1.0%
Q3 2018-0.5%-1.6%-6.3%
Q2 2018+10.1%+2.7%-2.7%
Q1 2018-0.9%+18.8%+23.1%
Q4 2017+19.0%+20.6%+44.3%
Q3 2017+7.9%+19.3%+15.8%
Q2 2017+2.8%+9.4%+0.0%
Q1 2017-8.7%-6.5%-6.5%
Q4 2016+4.7%+0.0%+0.0%
Q3 2016+34.9%+73.7%+73.7%
Q2 2016+0.0%-5.0%-20.0%
Q1 2016-23.2%
Q4 2015-29.6%
Q3 2015-12.0%
Q2 2015+6.3%
Q1 2015+4.3%
Q4 2014+71.2%
Q2 2014-16.7%
Q1 2014+0.0%
Q4 2013+23.4%
Q3 2013-17.9%
Q2 2013-16.6%
Q4 2012-4.3%
Q1 2013-4.3%
Q3 2012+18.5%
Q2 2012+0.0%
Q1 2012+0.0%
Q4 2011+0.0%
Q3 2011+900.0%
Q2 2011+0.0%
Q1 2011+0.0%
Q4 2010+5.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro